Ligand Enters Into Global License and Supply Agreement With Sanofi

Represented Ligand Pharmaceuticals Incorporated in connection with a global license and supply agreement with Sanofi to utilize Captisol in the development and commercialization of SAR-125844, a potent MET kinase inhibitor. Under the terms of the license, Ligand will be eligible to receive potential milestone payments, royalties on future net sales and revenue from Captisol material sales. Read the press release.

The deal team was led by Hayden Trubitt.